Cord Blood Transplant, Cyclophosphamide, Fludarabine, and Total-Body Irradiation in Treating Patients With High-Risk Hematologic Diseases
Public ClinicalTrials.gov record NCT06013423. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Optimized Cord Blood Transplantation for the Treatment of High-Risk Hematologic Malignancies in Adults and Pediatrics
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
This phase II trial studies how well giving an umbilical cord blood transplant together with cyclophosphamide, fludarabine, and total-body irradiation (TBI) works in treating patients with hematologic diseases. Giving chemotherapy, such as cyclophosphamide, fludarabine and thiotepa, and TBI before a donor cord blood transplant (CBT) helps stop the growth of cancer and abnormal cells and helps stop the patient's immune system from rejecting the donor's stem cells. When the healthy stem cells from a donor are infused into the patient they may help the patient's bone marrow make stem cells, red blood cells, white blood cells, and platelets. Sometimes the transplanted cells from a donor can make an immune response against the body's normal cells. Giving cyclosporine and mycophenolate mofetil after transplant may stop this from happening in patients with high-risk hematologic diseases.
Study identification
- NCT ID
- NCT06013423
- Recruitment status
- Recruiting
- Study type
- Interventional
- Phase
- Phase 2
- Enrollment
- 54 participants
Conditions and interventions
Conditions
- Acute Leukemia of Ambiguous Lineage
- Acute Lymphoblastic Leukemia
- Acute Myeloid Leukemia
- Blastic Plasmacytoid Dendritic Cell Neoplasm
- Hematopoietic and Lymphatic System Neoplasm
- Mixed Phenotype Acute Leukemia
- Myelodysplastic Syndrome
- Myeloproliferative Neoplasm
- Non-Hodgkin Lymphoma
- Chronic Myeloid Leukemia, BCR-ABL1 Positive
Interventions
- Biospecimen Collection Procedure
- Bone Marrow Aspirate Procedure
- Cyclophosphamide Drug
- Cyclosporine Drug
- Diagnostic Imaging Procedure
- Echocardiography Procedure
- Fludarabine Phosphate Drug
- Multigated Acquisition Scan Procedure
- Mycophenolate Mofetil Drug
- Survey Administration Other
- Thiotepa Drug
- Total-Body Irradiation Radiation
- Umbilical Cord Blood Transplantation Procedure
Procedure · Drug · Other + 1 more
Eligibility (public fields only)
- Age range
- 6 Months to 65 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jul 22, 2024
- Primary completion
- Oct 30, 2031
- Completion
- Oct 30, 2032
- Last update posted
- Jul 21, 2026
2024 – 2032
United States locations
- U.S. sites
- 1
- U.S. states
- 1
- U.S. cities
- 1
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| Fred Hutch/University of Washington Cancer Consortium | Seattle | Washington | 98109 | Recruiting |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT06013423, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jul 21, 2026 · Synced Sep 5, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT06013423 live on ClinicalTrials.gov.